Medytox Inc. announced the formation of Luvantas Inc. as its wholly-owned North American subsidiary. Luvantas is a new medical aesthetic company committed to bringing innovative solutions to the North American market by keeping the interests of customers, patients, and colleagues at the forefront. Luvantas is working with Medytox to seek approval for the upcoming introduction of NivobotulinumtoxinA to the United States and Canada.

A Biological License Application was submitted to the US FDA in December. More information on this formulation of Botulinum toxin will be provided once regulatory approvals are obtained. Luvantas intends to seek approval to introduce other innovative medical aesthetic offerings from Medytox, as well as partner with emerging companies and inventors to support the commercialization of unique medical aesthetic solutions.